Lenalidomide and pomalidomide, which are also commonly used to treat MM, can also upregulate DNAM-1 and NKG2D ligands through the downregulation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) that negatively regulate their transcription [37]. Here, IKZF3 is linked to Miyoshi myopathy.